

# Masato Nakai

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4722386/publications.pdf>

Version: 2024-02-01

46  
papers

811  
citations

430442

18  
h-index

552369

26  
g-index

47  
all docs

47  
docs citations

47  
times ranked

1042  
citing authors

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 1  | Efficacy and safety of daclatasvir and asunaprevir combination therapy in chronic hemodialysis patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2016, 51, 733-740.                               | 2.3 | 103       |
| 2  | Daclatasvir and asunaprevir in hemodialysis patients with hepatitis C virus infection: a nationwide retrospective study in Japan. <i>Journal of Gastroenterology</i> , 2018, 53, 119-128.                               | 2.3 | 49        |
| 3  | Early response and safety of lenvatinib for patients with advanced hepatocellular carcinoma in a real-world setting. <i>JGH Open</i> , 2020, 4, 54-60.  | 0.7 | 36        |
| 4  | Lenvatinib in patients with unresectable hepatocellular carcinoma who do not meet the REFLECT trial eligibility criteria. <i>Hepatology Research</i> , 2020, 50, 966-977.   | 1.8 | 35        |
| 5  | Retreatment with sofosbuvir, ledipasvir, and add-on ribavirin for patients who failed daclatasvir and asunaprevir combination therapy. <i>Journal of Gastroenterology</i> , 2017, 52, 1122-1129.                        | 2.3 | 32        |
| 6  | Entecavir treatment of hepatitis B virus-infected patients with severe renal impairment and those on hemodialysis. <i>Hepatology Research</i> , 2019, 49, 1294-1304.  | 1.8 | 32        |
| 7  | Safety and efficacy of daclatasvir and asunaprevir in hepatitis C virus-infected patients with renal impairment. <i>Hepatology Research</i> , 2017, 47, 1127-1136.  | 1.8 | 31        |
| 8  | Hepatitis B virus X protein impairs interferon signaling via upregulation of suppressor of cytokine signaling 3 and protein phosphatase 2A. <i>Journal of Medical Virology</i> , 2017, 89, 267-275.                     | 2.5 | 29        |
| 9  | Tenofovir disoproxil fumarate modulates lipid metabolism via hepatic CD36/PPAR-alpha activation in hepatitis B virus infection. <i>Journal of Gastroenterology</i> , 2021, 56, 168-180.                                 | 2.3 | 29        |
| 10 | Prevalence and characteristics of naturally occurring sofosbuvir resistance-associated variants in patients with hepatitis C virus genotype 1b infection. <i>Hepatology Research</i> , 2016, 46, 1294-1303.             | 1.8 | 27        |
| 11 | Prevalence, clinical course, and predictive factors of immune checkpoint inhibitor monotherapy-associated hepatitis in Japan. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1782-1788.      | 1.4 | 22        |
| 12 | Hepatitis B virus reactivation during hepatitis C direct-acting antiviral therapy in patients with previous HBV infection. <i>Journal of Hepatology</i> , 2017, 67, 1106-1108.  | 1.8 | 21        |
| 13 | Safety and efficacy of glecaprevir and pibrentasvir in Japanese hemodialysis patients with genotype 2 hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 641-649.                              | 2.3 | 21        |
| 14 | Lenvatinib suppresses cancer stem-like cells in HCC by inhibiting FGFR1 <sup>3</sup> signaling, but not FGFR4 signaling. <i>Carcinogenesis</i> , 2021, 42, 58-69.   | 1.3 | 21        |
| 15 | Anti-adipogenic and antiviral effects of L-carnitine on hepatitis C virus infection. <i>Journal of Medical Virology</i> , 2017, 89, 857-866.  | 2.5 | 20        |
| 16 | High serum angiopoietin-2 level predicts nonregression of liver stiffness measurement-based liver fibrosis stage after direct-acting antiviral therapy for hepatitis C. <i>Hepatology Research</i> , 2020, 50, 671-681. | 1.8 | 20        |
| 17 | Early response and safety of atezolizumab plus bevacizumab for unresectable hepatocellular carcinoma in patients who do not meet IMbrave150 eligibility criteria. <i>Hepatology Research</i> , 2021, 51, 979-989.       | 1.8 | 20        |
| 18 | Safety and efficacy of elbasvir and grazoprevir in Japanese hemodialysis patients with genotype 1b hepatitis C virus infection. <i>Journal of Gastroenterology</i> , 2019, 54, 78-86.                                   | 2.3 | 19        |

| #  | ARTICLE  | IF  | CITATIONS |
|----|--|-----|-----------|
| 19 | Novel Treatment of Hepatitis C Virus Infection for Patients with Renal Impairment. <i>Journal of Clinical and Translational Hepatology</i> , 2016, 4, 320-327.   | 0.7 | 18        |
| 20 | Effect of switching from tenofovir disoproxil fumarate to tenofovir alafenamide on lipid profiles in patients with hepatitis B. <i>PLoS ONE</i> , 2022, 17, e0261760.  | 1.1 | 17        |
| 21 | Serum granulysin levels as a predictor of serious telaprevir-induced dermatological reactions. <i>Hepatology Research</i> , 2015, 45, 837-845.   | 1.8 | 15        |
| 22 | Safety and efficacy of sofosbuvir and ribavirin for genotype 2 hepatitis C Japanese patients with renal dysfunction. <i>Hepatology Research</i> , 2018, 48, 529-538.   | 1.8 | 15        |
| 23 | Interferon (IFN) and Cellular Immune Response Evoked in RNA-Pattern Sensing During Infection with Hepatitis C Virus (HCV). <i>Sensors</i> , 2015, 15, 27160-27173.   | 2.1 | 14        |
| 24 | Baseline angiopoietin-2 and FGF19 levels predict treatment response in patients receiving multikinase inhibitors for hepatocellular carcinoma. <i>JGH Open</i> , 2020, 4, 880-888.   | 0.7 | 13        |
| 25 | Combination of neutrophil-to-lymphocyte ratio and early desinhibin carboxyprothrombin change ratio as a useful predictor of treatment response for hepatic arterial infusion chemotherapy against advanced hepatocellular carcinoma. <i>Hepatology Research</i> , 2017, 47, 533-541. | 1.8 | 13        |
| 26 | A Phase I Study of Combination Therapy with Sorafenib and 5-Fluorouracil in Patients with Advanced Hepatocellular Carcinoma. <i>Drugs in R and D</i> , 2017, 17, 381-388.  | 1.1 | 12        |
| 27 | Quantifying Protein-Specific N-Glycome Profiles by Focused Protein and Immunoprecipitation Glycomics. <i>Journal of Proteome Research</i> , 2019, 18, 3133-3141.   | 1.8 | 12        |
| 28 | Comparative Glycomic Analysis of Sialyl Linkage Isomers by Sialic Acid Linkage-Specific Alkylamidation in Combination with Stable Isotope Labeling of 1±2,3-Linked Sialic Acid Residues. <i>Analytical Chemistry</i> , 2019, 91, 13343-13348.  | 3.2 | 12        |
| 29 | Increased serum C-reactive protein and decreased urinary aquaporin 2 levels are predictive of the efficacy of tolvaptan in patients with liver cirrhosis. <i>Hepatology Research</i> , 2018, 48, E311-E319.  | 1.8 | 11        |
| 30 | Characteristics and Lenvatinib Treatment Response of Unresectable Hepatocellular Carcinoma with Iso-High Intensity in the Hepatobiliary Phase of EOB-MRI. <i>Cancers</i> , 2021, 13, 3633.   | 1.7 | 10        |
| 31 | Prediction of hepatocellular carcinoma using age and liver stiffness on transient elastography after hepatitis C virus eradication. <i>Scientific Reports</i> , 2022, 12, 1449.  | 1.6 | 9         |
| 32 | Effects of resistance-associated variants in genotype 2 hepatitis C virus on viral replication and susceptibility to anti-hepatitis C virus drugs. <i>Hepatology Research</i> , 2019, 49, 1275-1285.   | 1.8 | 8         |
| 33 | Computed tomography, not bioelectrical impedance analysis, is the proper method for evaluating changes in skeletal muscle mass in liver disease. <i>JCSM Rapid Communications</i> , 2020, 3, 103-114.  | 0.6 | 8         |
| 34 | Baseline elevated serum angiopoietin-2 predicts long-term non-regression of liver fibrosis after direct-acting antiviral therapy for hepatitis C. <i>Scientific Reports</i> , 2021, 11, 9207.  | 1.6 | 8         |
| 35 | Treatment outcomes of stereotactic body radiation therapy using a real-time tumor-tracking radiotherapy system for hepatocellular carcinomas. <i>Hepatology Research</i> , 2021, 51, 870-879.  | 1.8 | 8         |
| 36 | Frequency and Characteristics of Overestimated Renal Function in Japanese Patients with Chronic Liver Disease and Its Relation to Sarcopenia. <i>Nutrients</i> , 2021, 13, 2415.   | 1.7 | 8         |

| #  | ARTICLE   | IF  | CITATIONS |
|----|---|-----|-----------|
| 37 | Changes in Serum Growth Factors during Lenvatinib Predict the Post Progressive Survival in Patients with Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 232.   | 1.7 | 6         |
| 38 | The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment. <i>Internal Medicine</i> , 2019, 58, 943-947.          | 0.3 | 5         |
| 39 | Effect of palonosetron and dexamethasone administration on the prevention of gastrointestinal symptoms in hepatic arterial chemoembolization with epirubicin. <i>Supportive Care in Cancer</i> , 2020, 28, 3251-3257.                     | 1.0 | 5         |
| 40 | Durable response without recurrence to Tolvaptan improves long-term survival. <i>Journal of Gastroenterology</i> , 2020, 55, 1150-1161.   | 2.3 | 4         |
| 41 | Glecaprevir and Pibrentasvir for Japanese Patients with Human Immunodeficiency Virus and Genotype 3 Hepatitis C Virus Coinfection: A Report of Three Cases. <i>Internal Medicine</i> , 2019, 58, 797-802.                                 | 0.3 | 4         |
| 42 | Overestimated Renal Function in Patients with Liver Cirrhosis Predicts Poor Prognosis. <i>Hepatology Research</i> , 2022, , .   | 1.8 | 4         |
| 43 | Baseline serum angiopoietin-2 and VEGF levels predict the deterioration of the liver functional reserve during lenvatinib treatment for hepatocellular carcinoma. <i>PLoS ONE</i> , 2021, 16, e0247728.                                   | 1.1 | 3         |
| 44 | Add-on effects of fluvastatin in simeprevir/pegylated-interferon/ribavirin combination therapy for patients with genotype 1 hepatitis C virus infection: A randomized controlled study. <i>Hepatology Research</i> , 2018, 48, E146-E154. | 1.8 | 1         |
| 45 | Efficacy of rifaximin against covert hepatic encephalopathy and hyperammonemia in Japanese patients. <i>PLoS ONE</i> , 2022, 17, e0270786.  | 1.1 | 1         |
| 46 | Evaluation of clinical utility of PIVKA-II using a chemiluminescent immunoassay. <i>Acta Hepatologica Japonica</i> , 2019, 60, 397-404.   | 0.0 | 0         |